
The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.
The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.
Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.
Published: February 12th 2016 | Updated:
Published: June 22nd 2017 | Updated: